Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study

Blood Loss, Surgical Clinical Trial

Official title:

A Single Blinded Randomized Control Trial Comparing the Use of ARISTA Polysaccharide Hemostat in Total Knee Arthroplasty (TKA)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05522153
• Other study ID #: virtuamcmillan1
• Status: Recruiting
• Phase: Phase 1
• Start date: May 1, 2021
• Est. completion date: September 1, 2023

Study information

• Verified date: April 2023
• Source: Virtua Health, Inc.
• Contact: sean mcmillan, DO
• Phone: 6097479200
• Email: smcmillan[@]virtua.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To examine in Arista hemostatic powder results in less post-total knee arthroplasty blood loss, hematoma formation, and improved range of motion when compared to patients who did not receive the product.

Description:

Patients will be recruited from the Hospital for Special Surgery and Our Lady of Lourdes Programs. Patients will be prospectively enrolled when Institutional Review Board (IRB) approval is obtained. All patients will be undergoing a primary unilateral total knee arthroplasty for a diagnosis of osteoarthritis. Once enrolled in the study, each patient will be randomized into one of two groups. Group A will undergo a TKA utilizing Arista MPH ® intra-operatively. Group B will undergo a TKA without Arista MPH ®. All patients will receive a baseline IV dose of tranexamic acid per weight based guidelines prior to incision. A thigh tourniquet will be utilized from prior to incision until wound closure is complete. Arista MPH ® will be used intra-operatively. A 5 gram vial of Arista MPH will be the standard of use. ARISTA will be used in accordance with the instructions for use. Additional need for Arista MPH ® usage during the case will be permitted and recorded. Standard electrocautory will be permitted, however additional thermal devices intended for hemostatic control will not be utilized. Pre-operative hemoglobin, hematocrit, PT, PTT, and INR will be per standard institutional protocol within 30 days of surgery. The hemoglobin and hematocrit will be repeated 24 hours after the procedure per standard physician protocol. IV fluids administered pre-op, intra-op and post op for the first 24 hours will be recorded. Administration of any blood products from the time of incision until 90 days post-op will be recorded. Blood loss will be calculated via standard HSS. Drains will not be utilized. The transfusion criteria is: a hemoglobin level of <8 g/dL or a hemoglobin level of <10 g/dL in a patient with symptomatic anemia or deemed at high risk because of notable underlying cardiac comorbidities. Blood will be administered 1 unit at a time, and the presence of symptoms or signs was reassessed. Pre-operative thigh circumference will be measured on the day of the surgery. For standardization, the circumference will be recorded 15 cm proximal to the superior pole of the patella. Post-operatively the thigh circumference will be measured at 24 hours, post-operative day 14 +/- 4 days, and post operatively at 3 months +/- 1 week. Post-operative knee range of motion will be recorded at 24 hours, post-operative day 14 +/- 4 days, and post-operatively at 3 months +/- 1 week. Pre-operative and post-operative day 14 (+/- 4 days) and post-operative 3 months (+/- 1 week) knee society short form scores will be collected All post-operative adverse events related to the procedure will be recorded. These invents include, but are not limited to: readmission, infection, prosthesis loosening, wound dehiscence, and wound drainage. All data will be de-identified and securely maintained in an IRB approved manner.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: September 1, 2023
• Est. primary completion date: March 17, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• • They willingly desire to participate and signed the informed consent
• Are between the ages of 18 and 100 years of age
• Have the mental capacity to provide consent
• Are undergoing a primary unilateral total knee arthroplasty

Exclusion Criteria:

• • allergy to Arista MPH®
• allergy to tranexamic acid
• preoperative hepatic or renal dysfunction
• serious cardiac or respiratory disease including coronary artery stent placement
• congenital or acquired coagulopathy as evidence by INR > 1.4 or PTT > 1.4 times normal
• thrombocytopenia as identified by a preoperative platelet count of < 150,000/mm3
• history of thromboembolic disease
• pregnant or breast feeding
• donated preoperative autologous blood
• diagnosis of inflammatory arthritis
• a preoperative hemoglobin < 10 g/dL.

Related Conditions & MeSH terms

• Blood Loss, Surgical

Intervention

Drug:
• Arista
hemostatic powder

Locations

Country	Name	City	State
United States	Virtua Health System	Marlton	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
Virtua Health, Inc.	Becton, Dickinson and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Loss	Calculated on standard hospital protocol	Time of incision until 90 days post-op
Secondary	Hematoma formation	Thigh circumference measurement 15 cm above the top of the patella	preoperatively, 24 hours postop, 14 days postop, 3 months post op
Secondary	Range of motion	Measured in degrees	24 hours postop, 14 days postop, 3 months post op